2023
-
Trials Show Promise for New Agents to Treat COPD
Several trial results for the treatment of COPD were shared at the 2023 International Conference. Gerard J. Criner, MD, and David M. Mannino III, MD, discussed findings from the BOREAS trial, expectations from the ongoing NOTUS trial, and data from the ENHANCE-1 and ENHANCE-2 studies.
-
Ongoing Trials, Genetic Breakthroughs Pave the Way for Progress in Bronchiectasis
Timothy R. Aksamit, MD, FCCP, and Mark Metersky, MD, FCCP, comment on updates from multiple studies making headway in treating bronchiectasis. These trials, presented at the ATS 2023 International Conference, reflect research focusing on the three pillars of the disease: infection, inflammation, and mucociliary milieu. The trials included phase three of PROMIS II and phase…
-
Researchers Report Positive Trial Results on Four Investigative Agents for Asthma, COPD, and PAH
Four highly anticipated trials were presented at the ATS 2023 International Conference. The trials included the TORREY Study of Seralutinib, the ENHANCE Trials of Nebulized Ensifentrine, the Phase 1b Study of SAR443765 in Mild-to-Moderate Asthma, and the BOREAS Study of Dupilumab in COPD Patients with Type 2 Inflammation. Robert P. Frantz, MD, summarized the findings…
-
Clinical Year in Review 3 Focuses on Asthma, Sarcoidosis, Sepsis, Sleep
The third session of the annual Clinical Year in Review explored the latest developments in asthma, sarcoidosis, sepsis, and sleep. Using Single Maintenance and Reliever Therapy recommendations for patients with asthma addresses issues of self-management and adherence often seen in this population, reported Vanessa Marie McDonald, PhD.
-
Final Clinical Year in Review Examines New Research in Lung Transplantation, Medical Education, Health Disparities, CF and non-CF Bronchiectasis
The final Clinical Year in Review session covered lung transplantation, medical education, health disparities, and cystic fibrosis/non-cystic fibrosis bronchiectasis. Race-based corrections in spirometry are not clinically derived, said Deepshikha Charan Ashana, MD, MBA, MS.
-
Panel Discusses Alternatives to Race-Specific Equations in Pulmonary Function Testing
Co-authors of “Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement” participated in a panel of experts to discuss the potential harms and benefits of race-specific reporting in PFTs and propose alternatives that better reflect the populations served. The shift from race-specific PFT equations to race-neutral, or indeed some other…
-
Clinical Year in Review Begins with Latest Developments in ARDS, Pulmonary Vascular Disease, COPD, ILD
The first of four Clinical Year in Review sessions highlighted the latest papers published on acute respiratory distress syndrome, pulmonary vascular disease, chronic obstructive pulmonary disease, and interstitial lung disease. Stephanie Christenson, MD, MS, discussed new approaches to change the course of COPD recommended by the Lancet Commission and incorporated into the 2023 GOLD Report.
-
Experts Discuss Impactful Papers on Lung Cancer, COVID-19, Palliative Care, and Critical Care in Second Clinical Year in Review
The second session of the Clinical Year in Review explored the latest developments in lung cancer, COVID-19, palliative care, and critical care. Tiffanie Jones, MD, MPH, MSCE, discussed how early mobilization of patients in the intensive care unit affects ICU-acquired weaknesses.
-
International Respiratory Societies Gather to Discuss Inequities in COPD Treatment
The Respiratory Societies of the Americas kicked off its first in-person session at the ATS 2023 International Conference with representatives from four societies discussing COPD, its effects on country-specific populations, and the impact of health policies in relation to COPD. In Brazil, COPD is present in 6 percent of deaths, reported Frederico Fernandes, MD, PhD.
-
President’s Forum Focuses on Early Life Antecedents of Adult Lung Disease
Experts convened to explain the importance of early detection of prenatal and childhood respiratory illnesses and exposure to possible factors that could lead to adult respiratory disease. Some of these factors include airborne pollutants, viral infections like asthma, small airways disease, and COPD. Preterm birth exacerbates problems with pulmonary function across the lifespan, explained Kara…